Crossmark

Radioimmunotherapy for non-Hodgkin's lymphoma: positioning, safety, and efficacy of 90Y-ibritumomab. 10 years of experience and follow-up

Crossref DOI link: https://doi.org/10.1016/j.remnie.2016.10.002

Published Print: 2017-01

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Martínez, A.

Martínez-Ramirez, M.

Martínez-Caballero, D.

Beneit, P.

Clavel, J.

Figueroa, G.

Verdú, J.
License Information

Text and Data Mining valid from 2017-01-01
More Information

This article is maintained by: Elsevier

Article Title: Radioimmunotherapy for non-Hodgkin's lymphoma: positioning, safety, and efficacy of 90Y-ibritumomab. 10 years of experience and follow-up

Journal Title: Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.remnie.2016.10.002

CrossRef DOI link to the associated document: https://doi.org/10.1016/j.remn.2016.05.004

Content Type: article

Copyright: © 2016 Elsevier España, S.L.U. and SEMNIM. All rights reserved.